Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DARE 
Dare Bioscience Inc (DARE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DARE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.67
1 Year Target Price $11.67
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.96% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.30M USD | Price to earnings Ratio - | 1Y Target Price 11.67 |
Price to earnings Ratio - | 1Y Target Price 11.67 | ||
Volume (30-day avg) 4 | Beta 1.11 | 52 Weeks Range 1.83 - 4.60 | Updated Date 08/29/2025 |
52 Weeks Range 1.83 - 4.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate 0.03 | Actual -0.45 |
Profitability
Profit Margin - | Operating Margin (TTM) 18079.54% |
Management Effectiveness
Return on Assets (TTM) -63.13% | Return on Equity (TTM) -994.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25293698 | Price to Sales(TTM) 751.51 |
Enterprise Value 25293698 | Price to Sales(TTM) 751.51 | ||
Enterprise Value to Revenue 490.7 | Enterprise Value to EBITDA -2.06 | Shares Outstanding 13479500 | Shares Floating 13337832 |
Shares Outstanding 13479500 | Shares Floating 13337832 | ||
Percent Insiders 1.03 | Percent Institutions 6.71 |
Upturn AI SWOT
Dare Bioscience Inc
Company Overview
History and Background
Daru00e9 Bioscience, Inc. is a biopharmaceutical company founded in 2015 focused on developing and marketing innovative products for women's health. It was formed through a reverse merger with Cerulean Pharma.
Core Business Areas
- Vaginal Health: Focuses on products related to vaginal health, including treatments for bacterial vaginosis, vulvovaginal atrophy, and contraception.
- Fertility: Developing novel approaches to fertility management and pregnancy.
- Sexual Health: Products for improving sexual health and addressing female sexual dysfunction.
Leadership and Structure
Sabrina Martucci Johnson serves as the President and CEO. The company has a board of directors and a management team responsible for various functions like clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- XACIATOu2122 (clindamycin phosphate vaginal gel, 2%): FDA-approved treatment for bacterial vaginosis in women. Market share is still growing; competing with metronidazole and clindamycin products from companies like Pfizer and Teva.
- Ovapreneu00ae: A hormone-free monthly vaginal contraceptive ring. Still in clinical development (Phase 3). Competitors include hormonal IUDs (Bayer, Allergan), oral contraceptives (numerous manufacturers) and barrier methods.
Market Dynamics
Industry Overview
The women's health market is driven by an aging population, increasing awareness of women's health issues, and technological advancements in treatments and diagnostics.
Positioning
Daru00e9 Bioscience is positioned as an innovator in women's health, focusing on addressing unmet needs with novel product candidates. They aim to differentiate themselves through innovative delivery mechanisms and hormone-free alternatives.
Total Addressable Market (TAM)
The global women's health market is estimated to be in the hundreds of billions of dollars. Dare is targetting specific sectors of this TAM through their niche products.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Experienced management team
- Focus on unmet needs in women's health
- FDA approval for XACIATOu2122
Weaknesses
- Limited financial resources
- Reliance on partnerships for development and commercialization
- High risk associated with clinical trials
- Currently unprofitable
Opportunities
- Expanding product portfolio through acquisitions and in-licensing
- Partnering with larger pharmaceutical companies
- Reaching new markets and geographies
- Capitalizing on increasing awareness of women's health issues
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BAYRY
- AGN
- PFE
- TEVA
Competitive Landscape
Daru00e9 Bioscience faces competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative product pipeline and focus on unmet needs in women's health, but it needs partnerships and further development to increase market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by milestones in product development and regulatory approvals.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline products. Analyst projections vary based on the perceived likelihood of success for Ovapreneu00ae and other pipeline candidates.
Recent Initiatives: Recent initiatives include securing FDA approval for XACIATOu2122, advancing Ovapreneu00ae into Phase 3 clinical trials, and exploring new partnerships to expand its product portfolio.
Summary
Dare Bioscience is a company with a focus on developing women's health products, possessing an innovative product pipeline and addressing significant unmet medical needs. They have one product approved, but rely on partnerships and equity offerings. They must successfully develop its products for financial growth, while navigating competition from established pharmaceutical giants and overcoming potential clinical trial failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Daru00e9 Bioscience Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies involves significant risks. Market share values are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dare Bioscience Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2014-04-10 | CEO, President, Principal Financial Officer, Secretary & Director Ms. Sabrina Martucci Johnson | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://darebioscience.com |
Full time employees 21 | Website https://darebioscience.com | ||
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.